Tower Research Capital (TRC)’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,225
| Closed | -$4.74K | – | 6119 |
|
|
2024
Q3 | $4.74K | Sell |
1,225
-2,357
| -66% | -$6.53K | ﹤0.01% | 4435 |
|
|
2024
Q2 | $8.31K | Buy |
3,582
+891
| +33% | +$2.3K | ﹤0.01% | 4368 |
|
|
2024
Q1 | $7.59K | Buy |
2,691
+1,117
| +71% | +$3.31K | ﹤0.01% | 4177 |
|
|
2023
Q4 | $5K | Sell |
1,574
-358
| -19% | -$1.22K | ﹤0.01% | 4890 |
|
|
2023
Q3 | $6.38K | Buy |
1,932
+429
| +29% | +$1.34K | ﹤0.01% | 4603 |
|
|
2023
Q2 | $4.96K | Sell |
1,503
-1,708
| -53% | -$6.03K | ﹤0.01% | 4880 |
|
|
2023
Q1 | $11K | Buy |
3,211
+414
| +15% | +$1.45K | ﹤0.01% | 4286 |
|
|
2022
Q4 | $10K | Buy |
2,797
+215
| +8% | +$1.41K | ﹤0.01% | 4103 |
|
|
2022
Q3 | $23K | Sell |
2,582
-698
| -21% | -$5.8K | ﹤0.01% | 3834 |
|
|
2022
Q2 | $26K | Buy |
3,280
+3,216
| +5,025% | +$25.7K | ﹤0.01% | 3528 |
|
|
2022
Q1 | $1K | Sell |
64
-22
| -26% | -$196 | ﹤0.01% | 5882 |
|
|
2021
Q4 | $1K | Buy |
86
+85
| +8,500% | +$714 | ﹤0.01% | 5912 |
|
|
2021
Q3 | $0 | Sell |
1
-122
| -99% | -$1.15K | ﹤0.01% | 6269 |
|
|
2021
Q2 | $1K | Sell |
123
-115
| -48% | -$1.28K | ﹤0.01% | 5279 |
|
|
2021
Q1 | $3K | Buy |
+238
| New | +$4K | ﹤0.01% | 4942 |
|
|
2020
Q2 | – | Sell |
-1,043
| Closed | -$9K | – | 5051 |
|
|
2020
Q1 | $9K | Buy |
1,043
+969
| +1,309% | +$13.5K | ﹤0.01% | 2091 |
|
|
2019
Q4 | $1K | Sell |
74
-3,783
| -98% | -$54K | ﹤0.01% | 3347 |
|
|
2019
Q3 | $55K | Buy |
3,857
+1,600
| +71% | +$23.5K | ﹤0.01% | 1732 |
|
|
2019
Q2 | $30K | Buy |
2,257
+1,459
| +183% | +$22K | ﹤0.01% | 1920 |
|
|
2019
Q1 | $14K | Sell |
798
-382
| -32% | -$5.7K | ﹤0.01% | 2490 |
|
|
2018
Q4 | $16K | Buy |
1,180
+877
| +289% | +$15.4K | ﹤0.01% | 2134 |
|
|
2018
Q3 | $7K | Sell |
303
-239
| -44% | -$7.27K | ﹤0.01% | 2976 |
|
|
2018
Q2 | $23K | Buy |
+542
| New | +$24.8K | ﹤0.01% | 2365 |
|
|
2018
Q1 | – | Sell |
-8
| Closed | -$1K | – | 3954 |
|
|
2017
Q4 | $1K | Sell |
8
-43
| -84% | -$3.56K | ﹤0.01% | 3383 |
|
|
2017
Q3 | $5K | Sell |
51
-321
| -86% | -$24.6K | ﹤0.01% | 3340 |
|
|
2017
Q2 | $25K | Buy |
372
+307
| +472% | +$38K | ﹤0.01% | 1113 |
|
|
2017
Q1 | $14K | Sell |
65
-16
| -20% | -$2.29K | ﹤0.01% | 1565 |
|
|
2016
Q4 | $8K | Buy |
+81
| New | +$9.13K | ﹤0.01% | 2797 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 4601 |
|
|
2016
Q1 | – | Sell |
-47
| Closed | -$15K | – | 5090 |
|
|
2015
Q4 | $15K | Buy |
47
+8
| +21% | +$2.6K | ﹤0.01% | 1634 |
|
|
2015
Q3 | $12K | Sell |
39
-89
| -70% | -$39.1K | ﹤0.01% | 2178 |
|
|
2015
Q2 | $51K | Sell |
128
-40
| -24% | -$17K | ﹤0.01% | 1354 |
|
|
2015
Q1 | $83K | Buy |
+168
| New | +$65.1K | 0.01% | 1049 |
|
|
2014
Q4 | – | Sell |
-261
| Closed | -$50K | – | 4806 |
|
|
2014
Q3 | $50K | Buy |
+261
| New | +$57.4K | 0.01% | 1535 |
|
|
2014
Q2 | – | Sell |
-33
| Closed | -$9K | – | 4740 |
|
|
2014
Q1 | $9K | Sell |
33
-234
| -88% | -$71.5K | ﹤0.01% | 2736 |
|
|
2013
Q4 | $53K | Sell |
267
-31
| -10% | -$5.51K | 0.01% | 1346 |
|
|
2013
Q3 | $51K | Buy |
298
+279
| +1,468% | +$44.9K | 0.01% | 1901 |
|
|
2013
Q2 | $3K | Buy |
+19
| New | +$2.69K | ﹤0.01% | 3344 |
|
Tower Research Capital (TRC)'s LUMO Position: Q4 2024 in Review
Tower Research Capital (TRC) sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 1,225 shares — an estimated $4.74K sold.
Tower Research Capital (TRC) first reported a position in LUMO in Q2 2013 and held it in 37 quarters. The position peaked at $83K in Q1 2015. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Tower Research Capital (TRC) reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,225 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $4.74K.
- Tower Research Capital (TRC) first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 37 quarters.
- Tower Research Capital (TRC)'s Lumos Pharma, Inc. Common Stock position peaked at $83K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.